Aytu BioPharma, Inc. logo

Aytu BioPharma, Inc.

AYTU

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Regular session

$2.28

−$0.09 · -3.80%

Aug 24, 12:29 PM ET

AYTU company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

59

Fair Value

Momentum

34

Weakening

Sentiment

52

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Joshua R. Disbrow
Listed since
Sep 25, 2008
Employees
83

Market position

Day range

Current $2.28

52-week range

Current $2.28

Open
$2.30
Previous close
$2.37
Volume
3.95K
0.11× average
Average volume
34.81K
Average daily volume
Market cap
24.47M USD
Beta
0.26
Market reference 1
50-day average
$2.2236
+2.54% above average
200-day average
$2.3737
-3.95% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.67M USD
P/E (TTM)
-0.53×
P/B (TTM)
0.68×
P/S (TTM)
0.43×
EV / EBITDA
-1.22×
Earnings yield
-99.07%
Free cash flow yield
-37.73%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.50%
Operating margin
-26.79%
Net margin
-60.17%
Return on equity
-71.51%
Return on assets
-10.92%
Return on invested capital
-10.85%

Financial health

Debt / equity
0.65×
Current ratio
1.26×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends94%19%-57%-133%Gross margin, FY2021: 44.49%Gross margin, FY2022: 52.02%Gross margin, FY2023: 62.04%Gross margin, FY2024: 75.26%Gross margin, FY2025: 69.04%Operating margin, FY2021: -89.70%Operating margin, FY2022: -113.69%Operating margin, FY2023: -15.89%Operating margin, FY2024: -2.44%Operating margin, FY2025: -11.79%Net margin, FY2021: -88.81%Net margin, FY2022: -112.53%Net margin, FY2023: -15.88%Net margin, FY2024: -24.31%Net margin, FY2025: -20.43%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 44.49%. Gross margin FY2022 52.02%. Gross margin FY2023 62.04%. Gross margin FY2024 75.26%. Gross margin FY2025 69.04%. Operating margin FY2021 -89.70%. Operating margin FY2022 -113.69%. Operating margin FY2023 -15.89%. Operating margin FY2024 -2.44%. Operating margin FY2025 -11.79%. Net margin FY2021 -88.81%. Net margin FY2022 -112.53%. Net margin FY2023 -15.88%. Net margin FY2024 -24.31%. Net margin FY2025 -20.43%.

Income trends

Revenue

66.38M USD+1.84%

Operating income

−7.83M USD-391.95%

Net income

−13.56M USD+14.40%
Income trends across reported periods129.13M USD42.21M USD−44.71M USD−131.64M USDRevenue, FY2021: 65.63M USDRevenue, FY2022: 96.67M USDRevenue, FY2023: 107.4M USDRevenue, FY2024: 65.18M USDRevenue, FY2025: 66.38M USDOperating income, FY2021: −58.87M USDOperating income, FY2022: −109.91M USDOperating income, FY2023: −17.07M USDOperating income, FY2024: −1.59M USDOperating income, FY2025: −7.83M USDNet income, FY2021: −58.29M USDNet income, FY2022: −108.78M USDNet income, FY2023: −17.05M USDNet income, FY2024: −15.84M USDNet income, FY2025: −13.56M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 65.63M USD. Revenue FY2022 96.67M USD. Revenue FY2023 107.4M USD. Revenue FY2024 65.18M USD. Revenue FY2025 66.38M USD. Operating income FY2021 −58.87M USD. Operating income FY2022 −109.91M USD. Operating income FY2023 −17.07M USD. Operating income FY2024 −1.59M USD. Operating income FY2025 −7.83M USD. Net income FY2021 −58.29M USD. Net income FY2022 −108.78M USD. Net income FY2023 −17.05M USD. Net income FY2024 −15.84M USD. Net income FY2025 −13.56M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue66.38M USD65.18M USD107.4M USD96.67M USD65.63M USD
Cost of goods sold20.55M USD16.13M USD40.77M USD46.39M USD36.43M USD
Gross profit45.83M USD49.05M USD66.63M USD50.28M USD29.2M USD
Research and development1.33M USD2.77M USD4.1M USD12.66M USD5.62M USD
Selling, general, and administrative38.29M USD42.04M USD70.08M USD69.88M USD55.81M USD
Operating expenses53.66M USD50.65M USD83.7M USD160.19M USD88.07M USD
Interest income14K USD
Interest expense3.7M USD4.79M USD4.96M USD147.5M USD
Depreciation and amortization5.38M USD6.73M USD8.82M USD10.15M USD9.2M USD
Operating income−7.83M USD−1.59M USD−17.07M USD−109.91M USD−58.87M USD
Net income−13.56M USD−15.84M USD−17.05M USD−108.78M USD−58.29M USD

Company facts updated Aug 24, 2026.

AYTU peers

ETFs holding AYTU

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research AYTU

research.disclaimer